Figure 1.
Non-viral and viral delivery systems in pulmonary vascular cells. 7‑NH2terminus-deleted dominant negative inhibitor of the MCP-1 (7ND MCP‑1); Angiopoietin 1 (Ang‑1); Angiotensin II (Ang II); Bone morphogenetic protein receptor type 2 (BMPR2); Cluster of differentiation 40 (CD‑40); Calcitonin gene-related peptide (CGRP); C‑X‑C chemokine receptor type 4 (CXCR-4); Galectin‑3 (Gal‑3); Fas-induced apoptosis (FIA); Forkhead box O1 (FoxO1); Hypoxia inducible factor‑1α (HIF‑1α); Inhibitor of kappa B mutant (IκBΔN); Intercellular adhesion molecule-1 (ICAM-1); Interleukin 10, (IL‑10); Monocyte chemoattractant protein-1 (MCP‑1); Nitric Oxide (NO); Nuclear factor κB (NF‑κB); Phosphatidylinositol 3-kinase (PI3K); Prolyl hydroxylase domain (PHD); Prostacyclin synthase (PGIS); Ras association domain family 1A (RASSF1A); Sarco‑/endoplasmic reticulum calcium-ATPase 2a (SERCA2a); SMC-specific Rho-associated coiled-coil containing protein kinase 2 (SM22α/ROCK2); Tissue inhibitor matrix metalloproteinase 1 (TIMP‑1); Transgelin (Tagln); Transient receptor potential-1 (Trp1); Tryptophan hydroxylase-1 (Tph1); Tyrosine-protein kinase receptor (Tie2); Twist related protein 1 (Twist); Vascular endothelial growth factor (VEGF); Voltage-gated potassium channel member 5 (Kv1.5); Zinc Finger Protein 580 (ZNF580).